Abstract: Objective To evaluate the efficacy and safety of platinum-based chemotherapy in elderly patients with advanced nonsmall cell lung cancer（NSCLC）.Methods Clinical data of elderly patients（≥65 years）with advanced NSCLC who were treated by platinum-based chemotherapy were analyzed retrospectively.Cisplatin 50-60 mg／m2 or carboplatin（AUC=45）d1，paclitaxel 135-150mg／m2 d1 or vinorelbine 25mg／m2 d1，d8 or gemcitabine 1000mg／m2 d1，d8，was administered intravenously with a 3-4 weeks cycle. Results Among the patients，44（38.3％）patients were treated with paclitaxel，31（27.0％）patients with gemcitabine,40（34.7％）patients with vinorelbine，respectivety.The overall response rate was 26.1％ and disease control rate was 76.5%. The median progression free survival（PFS）was 5.5 months and median overall survival（OS）was 14.0 months.1-，2-year survival rates were 50% and 15% respectively. The major side effect was bone marrow suppression，especially neutropenia and thrombocytopenia.The adverse events were manageable.There was a trend towards an increase in PFS and OS，which reached statistical significance in ECOG and platinum subgroups（P＜0.05）. Conclusion The platinum-based combined chemotherapy is effective and well tolerated in elderly patients with advanced NSCLC.